Pharma
Bristol Myers Squibb Company
10
Articles
Mentioned
Top Role
Jan 19, 2026
First Mention
Apr 11, 2026
Last Mention
6.53
Relevance Score
Intelligence Brief
Overview
Bristol Myers Squibb is a global biopharmaceutical company focusing on oncology, immunology, and cardiovascular diseases. Its significance lies in its robust pipeline and strategic acquisitions, such as the Celgene deal, which have positioned it strongly in the market despite recent challenges like the Revlimid sales decline.
Assets & Portfolio
BMS owns blockbuster drugs like Eliquis and Opdivo, and has a strong presence in the oncology space. The acquisition of Celgene brought in Revlimid, although its revenue is now under pressure from generics. They also have a significant portfolio in immunology and cardiovascular therapies.
Partnerships & Deals
BMS collaborates with Pfizer on Eliquis, a key anticoagulant, though facing pricing pressures. Their partnership with Relay Therapeutics involves a $50 million upfront payment, focusing on AI-driven drug discovery. These alliances aim to bolster BMS's R&D capabilities and market reach.
Pipeline & Development
BMS is advancing its oncology pipeline to maintain leadership in the sector, particularly in lung cancer treatments. They are also investing in AI-driven drug discovery, although recent deals haven't significantly altered their strategic direction. The focus remains on next-gen therapies to offset revenue declines from older products.
Competitive Position
BMS is a leader in oncology, competing closely with Merck and Pfizer. However, Roche's recent lung cancer trial results could disrupt this standing. They are maintaining a competitive edge through strategic acquisitions and a strong pipeline, but face challenges from generic erosion and pricing pressures.
Technology & Innovation
BMS is investing in AI and data-driven drug discovery, but their efforts haven't yet reshaped their strategic direction. Their partnership with Relay Therapeutics reflects a commitment to integrating advanced technologies into their R&D processes. However, they are not leading in AI adoption compared to peers like J&J.
Growth Outlook
BMS is in a period of consolidation, focusing on offsetting revenue losses from products like Revlimid with new pipeline launches. The growth trajectory is steady, driven by oncology and cardiovascular segments, but challenged by pricing pressures and generic competition.
Industry Trend Fit
BMS's capabilities align with industry trends like AI drug discovery and value-based care, though their impact is still emerging. The IRA pricing negotiations have pressured key revenue drivers like Eliquis, highlighting the need for strategic adaptation. Their focus on innovative therapies positions them well for future industry shifts.
Coverage Timeline
April 2026
Roche’s Lung Cancer Trial Upsets the Oncology Table: Market Dynamics and Competitor Response
The Week
Competitor
Apr 11, 2026
This result changes Roche’s standing in the oncology pecking order. They’d been trailing Merck and Bristol Myers in first-line NSCLC.
Apr 11, 2026
GSK’s £33 million Exscientia partnership, or those $50 million BMS-Relay up-fronts, didn’t reshape anyone’s strategy.
Apr 11, 2026
Eliquis provides a cautionary tale, even with solid new launches, BMS and Pfizer are watching net sales erosion outpace gains from the next-gen products.
GSK Names First Chief Diversity Officer Amidst Regulatory Challenges and Product Pipeline Expansion: Strategic Implications
People
Mentioned
Apr 9, 2026
GSK’s SG A as a percent of revenue hit 29.8 percent last year, roughly 120 basis points above Bristol Myers Squibb and almost 300 above AstraZeneca.
Apr 2, 2026
Last year, the drug raked in over $13 billion in US sales for Bristol Myers Squibb and Pfizer.
March 2026
The Week in Pharma: Lilly Bets $2.5B on Alzheimer’s, Pfizer Shifts Oncology Gears, Policy Upheaval Hits Drug Discovery
The Week
Competitor
Mar 14, 2026
For context, this puts Pfizer trailing Merck and Bristol Myers, despite outspending them both on pipeline deals since 2020.
February 2026
Feb 21, 2026
Bristol Myers Squibb missed consensus by 11%, citing weaker Revlimid sales after generics accelerated their push.
IRA Price Negotiation Year One: What the Numbers Reveal About CMS, Drugmakers, and the Real Deals
Policy
Mentioned
Feb 5, 2026
Eliquis (apixaban) and Xarelto (rivaroxaban) bore the brunt, with an initial ceiling price set about 65% off list.
January 2026
IRA Price Negotiation Year One: Who Blinked, Who Balked, and What's Next for Big Ticket Drugs
Policy
Mentioned
Jan 22, 2026
Eliquis (BMS/Pfizer) was among the list of drugs up for negotiation.
Jan 19, 2026
Bristol Myers Squibb’s Celgene bet? 10x.